{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:58:25Z","timestamp":1769529505956,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472441"],"award-info":[{"award-number":["81472441"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81501205"],"award-info":[{"award-number":["81501205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza\u2122). The goal of this research is to evaluate the side effects and short-term efficacy in advanced ovarian cancer patients who administered Olaparib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with ovarian cancer, fallopian tube cancer and peritoneal cancer that treated with Olaparib in The Affiliated Cancer Hospital of Nanjing Medical University between September 2018 and June 2019 were recruited. The drug associated Adverse Events (AEs) were collected and short-term efficacy were analyzed by modified Response Evaluation Criteria in Solid Tumors (mRECIST) .<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of all 28 enrolled patients, 92.9% were ovarian cancer, 7.1% were fallopian tube cancer, and 39.3% cases harbored germline BRCA-mutation. There were 6(21.4%) patients received Olaparib after multi-line chemotherapy, and 10 patients (35.7%) as second-line maintenance therapy and 2 patients (7.1%) as first-line maintenance therapy. There were still other 10 cases (35.7%) received Olaparib as exploratory therapy. Abdominal distention, decreased blood pressure, increased body hair, thirsty, burning sensation of stomach and leg swelling were newly reported AEs. Serious Adverse Events(SAEs) were usually managed by dose interruption or dose reduction, rather than discontinuation. 3 patients discontinued treatment, 8 patients received reduced dose of Olaparib, and 4 patients stopped therapy after the alleviation of AEs. Of all 28 enrolled cases, in monotherapy group, 1 of 6 patients achieved stable disease(SD) and also 2 patients achieved stable disease(SD) combined with anti-angiogenic drugs when disease progressed. 2 patients achieved complete remission(CR) and 3 patients were stable with exploratory therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The AEs of Olaparib were all manageable. For the first time, we also identified several AEs such as abdominal distention, decreased blood pressure, increased body hair, thirsty, burning sensation of stomach and leg swelling during the follow-up which have not been reported. The short-term efficacy was observed in some exploratory cases that provided new potential indication to PARPi-related clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13048-019-0594-1","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T02:02:40Z","timestamp":1574906560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China"],"prefix":"10.1186","volume":"12","author":[{"given":"Jing","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-4749","authenticated-orcid":false,"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"1","key":"594_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ijgc-2018-000016","volume":"29","author":"KK Gupta","year":"2019","unstructured":"Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019;29(1):195\u2013200.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"594_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"594_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"key":"594_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ctrv.2018.06.008","volume":"69","author":"KE Broekman","year":"2018","unstructured":"Broekman KE, et al. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores. Cancer Treat Rev. 2018;69:233\u201342.","journal-title":"Cancer Treat Rev"},{"key":"594_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim A, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"594_CR6","doi-asserted-by":"publisher","first-page":"e8816","DOI":"10.15252\/emmm.201708816","volume":"10","author":"Matthew J Schiewer","year":"2018","unstructured":"Schiewer MJ, et al. PARP-1 regulates DNA repair factor availability. EMBO Mol Med. 2018:10(12).","journal-title":"EMBO Molecular Medicine"},{"issue":"3","key":"594_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33(3):244\u201350.","journal-title":"J Clin Oncol"},{"issue":"11","key":"594_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"9","key":"594_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"26","key":"594_CR10","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"1","key":"594_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/GCO.0000000000000507","volume":"31","author":"C Washington","year":"2019","unstructured":"Washington C, Gunderson CC, Moore KN. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Curr Opin Obstet Gynecol. 2019;31(1):4\u201311.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"594_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"594_CR13","doi-asserted-by":"crossref","unstructured":"Penson RT, et al. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. 2019. Proc Am Soc Clin Oncol.","DOI":"10.1136\/ijgc-2019-IGCS.33"},{"key":"594_CR14","doi-asserted-by":"crossref","unstructured":"Vanderstichele A, et al. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. 2019. Proc Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2019.37.15_suppl.5507"},{"key":"594_CR15","doi-asserted-by":"crossref","unstructured":"Lheureux S, et al. Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer\u2014A Princess Margaret Consortium\u2013GCIG Phase II Trial. 2019. Proc Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2019.37.15_suppl.5521"},{"key":"594_CR16","doi-asserted-by":"crossref","unstructured":"Wu L, et al. Olaparib maintenance therapy in patients (pts) with a BRCA1 and\/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. 2019. Proc Am Soc Clin Oncol.","DOI":"10.1093\/annonc\/mdz426.006"},{"issue":"5","key":"594_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"key":"594_CR18","unstructured":"Hawsawi YM, et al. Mol Genet Genomic Med. 2019:e879."},{"issue":"20","key":"594_CR19","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2016.69.4935","volume":"35","author":"J Lecarpentier","year":"2017","unstructured":"Lecarpentier J, et al. Prediction of breast and prostate Cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 2017;35(20):2240\u201350.","journal-title":"J Clin Oncol"},{"issue":"12","key":"594_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/cancers9050042","volume":"9","author":"Jonas Cicenas","year":"2017","unstructured":"Cicenas J, et al. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers (Basel). 2017:9(5).","journal-title":"Cancers"},{"issue":"6","key":"594_CR21","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bjd.13626","volume":"172","author":"PV Gumaste","year":"2015","unstructured":"Gumaste PV, et al. Skin cancer risk in BRCA1\/2 mutation carriers. Br J Dermatol. 2015;172(6):1498\u2013506.","journal-title":"Br J Dermatol"},{"key":"594_CR22","doi-asserted-by":"crossref","unstructured":"Kindler HL, et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. Proc Am Soc Clin Oncol. 2019.","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0594-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T02:37:48Z","timestamp":1665110268000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0594-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the institutional review board of Jiangsu Cancer Hospital, Nanjing Medical University, China. The informed consent requirement was waived. The committee\u2019s reference number was Jiangsu Cancer Hospital\u2019s Ethical Committee 2016-05-01.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}